Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker AMRX
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | 50,000 | $879.7K | — | Aug 13, 2026 | Form 4 ↗ 1 day later · 50,000 shares | Form 144 ↗ |
| Aug 12, 2026 | Nikita Shah Officer | AMRX Amneal Pharmaceuticals, Inc. | 146,403 | $2.6M | — | Aug 12, 2026 | Form 4 ↗ 1 day later · 146,403 shares | Form 144 ↗ |
| Aug 12, 2026 | Jason Daly OFFICER | AMRX Amneal Pharmaceuticals, Inc. | 210,000 | $3.6M | — | Aug 11, 2026 | Form 4 ↗ 1 day later · 216,613 shares | Form 144 ↗ |
| Aug 11, 2026 | J. Kevin Buchi Director | AMRX Amneal Pharmaceuticals, Inc. | 168,573 | $2.9M | — | Aug 11, 2026 | — | Form 144 ↗ |
| May 11, 2026 | Deborah Autor DIRECTOR | AMRX Amneal Pharmaceuticals, Inc. | 34,819 | $450.4K | 10b5-1 | May 11, 2026 | Form 4 ↗ 1 day later · 34,819 shares | Form 144 ↗ |
| Nov 17, 2025 | Ted C. Nark Director | AMRX Amneal Pharmaceuticals, Inc. | 50,000 | $591.3K | — | Nov 17, 2025 | Form 4 ↗ 2 days later · 50,000 shares | Form 144 ↗ |
| Nov 12, 2025 | Nikita Shah OFFICER | AMRX Amneal Pharmaceuticals, Inc. | 131,856 | $1.6M | — | Nov 12, 2025 | Form 4 ↗ 2 days later · 131,856 shares | Form 144 ↗ |
| Aug 27, 2025 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | 32,000 | $293.8K | — | Aug 27, 2025 | Form 4 ↗ 1 day later · 32,000 shares | Form 144 ↗ |
| Aug 22, 2025 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 36,796 | $356.9K | — | Aug 22, 2025 | Form 4 ↗ 3 days later · 120,832 shares | Form 144 ↗ |
| Aug 22, 2025 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 84,036 | $818.9K | — | Aug 22, 2025 | Form 4 ↗ 3 days later · 120,832 shares | Form 144 ↗ |
| Aug 20, 2025 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 175,000 | $1.6M | — | Aug 20, 2025 | Form 4 ↗ 2 days later · 279,244 shares | Form 144 ↗ |
| Aug 20, 2025 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 104,244 | $969.5K | — | Aug 20, 2025 | Form 4 ↗ 2 days later · 279,244 shares | Form 144 ↗ |
| Aug 15, 2025 | Konidaris Tasos Officer | AMRX Amneal Pharmaceuticals, Inc. | 219,159 | $2.1M | — | Aug 15, 2025 | Form 4 ↗ same day · 499,730 shares | Form 144 ↗ |
| Aug 14, 2025 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 71,694 | $663.1K | — | Aug 14, 2025 | Form 4 ↗ 1 day later · 71,694 shares | Form 144 ↗ |
| Aug 13, 2025 | Konidaris Tasos Officer | AMRX Amneal Pharmaceuticals, Inc. | 169,206 | $1.6M | — | Aug 13, 2025 | Form 4 ↗ 2 days later · 499,730 shares | Form 144 ↗ |
| Aug 13, 2025 | Konidaris Tasos Officer | AMRX Amneal Pharmaceuticals, Inc. | 111,635 | $1.0M | — | Aug 13, 2025 | Form 4 ↗ 2 days later · 499,730 shares | Form 144 ↗ |
| Aug 12, 2025 | Jason B. Daly Officer | AMRX Amneal Pharmaceuticals, Inc. | 22,000 | $198.0K | — | Aug 12, 2025 | Form 4 ↗ 1 day later · 22,000 shares | Form 144 ↗ |
| Aug 12, 2025 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 33,436 | $304.1K | — | Aug 12, 2025 | Form 4 ↗ 1 day later · 33,436 shares | Form 144 ↗ |
| Aug 12, 2025 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 50,000 | $453.0K | — | Aug 12, 2025 | Form 4 ↗ 1 day later · 50,000 shares | Form 144 ↗ |
| May 16, 2025 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 49,140 | $368.6K | — | May 16, 2025 | Form 4 ↗ 3 days later · 49,140 shares | Form 144 ↗ |
| May 12, 2025 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | 50,000 | $378.5K | — | May 12, 2025 | Form 4 ↗ 1 day later · 50,000 shares | Form 144 ↗ |
| May 2, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | 160,000 | $1.2M | 10b5-1 | May 2, 2025 | Form 4 ↗ 4 days later · 8,668 shares | Form 144 ↗ |
| Mar 14, 2025 | Patel Tushar Bhikhubhai 10% Stockholder | AMRX Amneal Pharmaceuticals, Inc. | 5.00M | $43.8M | — | Mar 14, 2025 | Form 4 ↗ 3 days later · 5.00M shares | Form 144 ↗ |
| Mar 5, 2025 | Alva Emily Peterson Director | AMRX Amneal Pharmaceuticals, Inc. | 85,000 | $754.0K | — | Mar 5, 2025 | Form 4 ↗ 2 days later · 80,000 shares | Form 144 ↗ |
| Mar 5, 2025 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 125,000 | $1.1M | — | Mar 5, 2025 | Form 4 ↗ 2 days later · 125,000 shares | Form 144 ↗ |
| Mar 5, 2025 | Jason B. Daly Officer | AMRX Amneal Pharmaceuticals, Inc. | 90,000 | $792.0K | — | Mar 5, 2025 | Form 4 ↗ 2 days later · 90,000 shares | Form 144 ↗ |
| Mar 5, 2025 | Konidaris Tasos Officer | AMRX Amneal Pharmaceuticals, Inc. | 100,000 | $884.0K | — | Mar 5, 2025 | Form 4 ↗ 2 days later · 100,000 shares | Form 144 ↗ |
| Jan 2, 2025 | Gautam J Patel Director | AMRX Amneal Pharmaceuticals, Inc. | 320,000 | $2.6M | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 4 days later · 17,410 shares | Form 144 ↗ |
| Nov 22, 2024 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | 17,058 | $142.2K | — | Nov 22, 2024 | Form 4 ↗ 4 days later · 17,058 shares | Form 144 ↗ |
| Nov 21, 2024 | Deborah M. Autor Director | AMRX Amneal Pharmaceuticals, Inc. | 50,000 | $419.0K | — | Nov 21, 2024 | Form 4 ↗ 4 days later · 40,000 shares | Form 144 ↗ |
| Nov 15, 2024 | Jason B. Daly Officer | AMRX Amneal Pharmaceuticals, Inc. | 57,322 | $487.2K | — | Nov 15, 2024 | Form 4 ↗ 4 days later · 43,657 shares | Form 144 ↗ |
| Aug 14, 2024 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 70,000 | $546.0K | — | Aug 14, 2024 | — | Form 144 ↗ |
| Aug 14, 2024 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 70,000 | $550.2K | — | Aug 14, 2024 | — | Form 144 ↗ |
| Aug 14, 2024 | Shah Nikita Officer | AMRX Amneal Pharmaceuticals, Inc. | 30,000 | $235.8K | — | Aug 14, 2024 | — | Form 144 ↗ |
| May 16, 2024 | Deborah M. Autor Director | AMRX Amneal Pharmaceuticals, Inc. | 38,000 | $261.0K | — | May 16, 2024 | — | Form 144 ↗ |
| Aug 11, 2023 | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 8,302 | $32.8K | — | Aug 11, 2023 | — | Form 144 ↗ |
| Aug 11, 2023 amended | Andrew S. Boyer Officer | AMRX Amneal Pharmaceuticals, Inc. | 21,000 | $88.6K | — | Aug 11, 2023 | — | Form 144/A ↗ |
| Aug 11, 2023 | Andrew S. Boyer Director | AMRX Amneal Pharmaceuticals, Inc. | 21,000 | $88.6K | — | Aug 11, 2023 | — | Form 144 ↗ |
38 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances